Abstract

Atogepant (Aquipta) is a new oral CGRP‐receptor antagonist indicated for the prophylaxis of migraine in adults. This article discusses its indication, efficacy and adverse effects.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call